BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia

Established genetic biomarkers in chronic lymphocytic leukemia (CLL) have been useful in predicting response to chemoimmunotherapy but are less predictive of response to targeted therapies. With several such targeted therapies now approved for CLL, identifying novel, non-genetic predictive biomarker...

Full description

Bibliographic Details

Main Authors:	Chong, Stephen Jun Fei (Author) , Lu, Junyan (Author) , Valentin, Rebecca (Author) , Lehmberg, Timothy Z. (Author) , Eu, Jie Qing (Author) , Wang, Jing (Author) , Zhu, Fen (Author) , Kong, Li Ren (Author) , Fernandes, Stacey M. (Author) , Zhang, Jeremy (Author) , Herbaux, Charles (Author) , Goh, Boon Cher (Author) , Brown, Jennifer R. (Author) , Niemann, Carsten U. (Author) , Huber, Wolfgang (Author) , Zenz, Thorsten (Author) , Davids, Matthew S. (Author)
Format:	Article (Journal)
Language:	English
Published:	03 March 2025
In:	Molecular cancer Year: 2025, Volume: 24, Pages: 1-19
ISSN:	1476-4598
DOI:	10.1186/s12943-025-02260-7
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12943-025-02260-7
Author Notes:	Stephen Jun Fei Chong, Junyan Lu, Rebecca Valentin, Timothy Z. Lehmberg, Jie Qing Eu, Jing Wang, Fen Zhu, Li Ren Kong, Stacey M. Fernandes, Jeremy Zhang, Charles Herbaux, Boon Cher Goh, Jennifer R. Brown, Carsten U. Niemann, Wolfgang Huber, Thorsten Zenz and Matthew S. Davids